Scinai Immunotherapeutics (SCNI) Common Equity (2024 - 2025)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Scinai Immunotherapeutics (SCNI) has disclosed Common Equity for 2 consecutive years, with $8.1 million as the latest value for Q4 2025.

• Quarterly Common Equity fell 18.78% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Dec 2025, down 18.78% year-over-year, with the annual reading at $8.1 million for FY2025, 18.78% down from the prior year.
• Common Equity hit $8.1 million in Q4 2025 for Scinai Immunotherapeutics, down from $10.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $10.0 million in Q4 2024 to a low of $8.1 million in Q4 2025.

Peer Comparison